CO2022000405A2 - Polimorfos de un inhibidor de cinasas macrocíclicas - Google Patents

Polimorfos de un inhibidor de cinasas macrocíclicas

Info

Publication number
CO2022000405A2
CO2022000405A2 CONC2022/0000405A CO2022000405A CO2022000405A2 CO 2022000405 A2 CO2022000405 A2 CO 2022000405A2 CO 2022000405 A CO2022000405 A CO 2022000405A CO 2022000405 A2 CO2022000405 A2 CO 2022000405A2
Authority
CO
Colombia
Prior art keywords
polymorphs
kinase inhibitor
macrocyclic kinase
mammals
cancer
Prior art date
Application number
CONC2022/0000405A
Other languages
English (en)
Spanish (es)
Inventor
Evan W Rogers
Wei Deng
Jing Liu
Han Zhang
Yuelie Lu
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of CO2022000405A2 publication Critical patent/CO2022000405A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CONC2022/0000405A 2019-06-19 2022-01-19 Polimorfos de un inhibidor de cinasas macrocíclicas CO2022000405A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US202063036102P 2020-06-08 2020-06-08
PCT/US2020/037892 WO2020257169A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor

Publications (1)

Publication Number Publication Date
CO2022000405A2 true CO2022000405A2 (es) 2022-04-29

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000405A CO2022000405A2 (es) 2019-06-19 2022-01-19 Polimorfos de un inhibidor de cinasas macrocíclicas

Country Status (15)

Country Link
US (1) US20220411439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986413A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022537385A (cg-RX-API-DMAC7.html)
KR (1) KR20220046549A (cg-RX-API-DMAC7.html)
CN (1) CN114025765A (cg-RX-API-DMAC7.html)
AU (1) AU2020294627A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025786A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143043A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000405A2 (cg-RX-API-DMAC7.html)
IL (1) IL288982A (cg-RX-API-DMAC7.html)
MX (1) MX2021015756A (cg-RX-API-DMAC7.html)
PE (1) PE20220135A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553174A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115090A (cg-RX-API-DMAC7.html)
WO (1) WO2020257169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (ru) * 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
BR112018000297A2 (pt) * 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CA3069554A1 (en) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
RS63787B1 (sr) * 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti

Also Published As

Publication number Publication date
PH12021553174A1 (en) 2022-08-01
WO2020257169A1 (en) 2020-12-24
MX2021015756A (es) 2022-01-27
AU2020294627A1 (en) 2022-02-17
IL288982A (en) 2022-02-01
PE20220135A1 (es) 2022-01-27
JP2022537385A (ja) 2022-08-25
BR112021025786A2 (pt) 2022-02-01
KR20220046549A (ko) 2022-04-14
CA3143043A1 (en) 2020-12-24
TW202115090A (zh) 2021-04-16
EP3986413A4 (en) 2023-06-14
CN114025765A (zh) 2022-02-08
US20220411439A1 (en) 2022-12-29
EP3986413A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
MX2021008145A (es) Polimorfo de macrociclo de diarilo.
CO2020015226A2 (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MX2018000718A (es) Macrociclos de diarilo quirales y usos de los mismos.
MX2021013661A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
CO2021016765A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CL2021002995A1 (es) (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1.
IL276501A (en) CGAS inhibitors containing 2,3,4,5-tetrahydro-1H-pyrado[B-4,3]indoles for the treatment of autoinflammatory diseases
MX376174B (es) 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
MX2023007162A (es) Macrociclos y sus usos.
MX2019003649A (es) Inhibidores selectivos de jak1 novedosos y usos de los mismos.
ECSP099400A (es) Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO2019005538A2 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1
CO6420343A2 (es) [1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa
DOP2025000213A (es) [1,3]tiazolo[4,5-d]-pirimidin-7-onas como inhibidores de la nox4
CO2017003538A2 (es) Inhibidores de histona desmetilasa derivados de 2-oxipirido[ 3,4-d]pirimidin-4-ol
NI200700318A (es) Benzocicloheptapiridinas como inhibidores de la tirosina quinasa de receptor met
CO2026005573A2 (es) Compuestos heterobifuncionales y métodos de tratamiento de enfermedades
PE20191789A1 (es) Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa
PE20220135A1 (es) Polimorfos de un inhibidor de cinasas macrociclicas
MX2022010945A (es) Usos terapeuticos de compuestos macrociclicos.
MY203494A (en) 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative
CO2026004945A2 (es) Compuestos 5-oxo-4,5-dihidroimidazo[1,5-a]quinazolina como inhibidores de pi3k[alfa]